CERo Therapeutics
CERO
CERO was delisted on the 30th of October, 2025.
13 hedge funds and large institutions have $528K invested in CERo Therapeutics in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 13 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
1.19% more ownership
Funds ownership: 0% → 1.19% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
28% less funds holding
Funds holding: 18 → 13 (-5)
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
45% less capital invested
Capital invested by funds: $957K → $528K (-$430K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$616K |
| 2 |
PA
Parallel Advisors
San Francisco,
California
|
+$435K |
| 3 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
+$95.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$84.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$33.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$142K |
| 2 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$20K |
| 3 |
VPIM
Vanguard Personalized Indexing Management
Oakland,
California
|
-$14.1K |
| 4 |
CF
Cantor Fitzgerald
New York
|
-$10K |
| 5 |
Goldman Sachs
New York
|
-$9.75K |
CERO Hedge Fund Activity: Q1 2025 in Review
13 of the 7,461 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q1 2025, worth a combined $528K — down 45% from $957K a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CERO and 8 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $616K. The largest seller was Arch Venture Management, cutting an estimated $142K.
- 13 institutional investors held CERo Therapeutics (CERO) as of Q1 2025, down from 18 in Q4 2024.
- Funds reported $528K of CERo Therapeutics stock for Q1 2025, down 45% quarter-over-quarter.
- 8 funds opened new CERo Therapeutics positions in Q1 2025 and 13 closed out, a net change of -5 holders.
- The largest CERo Therapeutics buyer in Q1 2025 was Armistice Capital, an estimated $616K added.
- The largest CERo Therapeutics seller in Q1 2025 was Arch Venture Management, an estimated $142K sold.
Based on aggregated 13F filings for Q1 2025.